Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity

Despite substantial efforts in recent years toward the development of new vaccines and drugs against tuberculosis (TB), success has remained elusive. Immunotherapy of TB with mycobacterial Hsp65 as a DNA vaccine (DNA-hsp65) results in a reduction of systemic bacterial loads and lung tissue damage, b...

Full description

Saved in:
Bibliographic Details
Published in:Human Vaccines & Immunotherapeutics 2014, Vol.10 (5), p.1238-1243
Main Authors: Doimo, Nayara TS, Zárate-Bladés, Carlos R, Rodrigues, Rodrigo F, Tefé-Silva, Cristiane, Trotte, Marcele NS, Souza, Patrícia RM, Soares, Luana S, Rios, Wendy M, Floriano, Elaine M, Brandão, Izaira T, Masson, Ana P, Coelho, Verônica, Ramos, Simone G, Silva, Celio L
Format: Report
Language:English
Subjects:
autoimmune response
DNA vaccine
heat-shock protein
immunotherapy
tuberculosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite substantial efforts in recent years toward the development of new vaccines and drugs against tuberculosis (TB), success has remained elusive. Immunotherapy of TB with mycobacterial Hsp65 as a DNA vaccine (DNA-hsp65) results in a reduction of systemic bacterial loads and lung tissue damage, but the high homology of Hsp65 with the mammalian protein raises concern that pathological autoimmune responses may also be triggered. We searched for autoimmune responses elicited by DNA-hsp65 immunotherapy in mice chronically infected with TB by evaluating the humoral immune response and comprehensive histopathology using stereology. Cross-reactive antibodies between mycobacterial and mammalian Hsp60/65 were detected; however, no signs of pathological autoimmunity were found up to 60 days after the end of the therapy.
ISSN:2164-5515
2164-554X
DOI:10.4161/hv.28249